Free tool
FAERS Monitor: Tepezza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761143 or its brand name (Tepezza, Teprotumumab-Trbw). Reports on generic versions are filed under their own applications.
Reports
5,951
Serious
2,588
43% of reports
Hospitalization
505
Death reported
41
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- muscle spasms1,156
- fatigue822
- tinnitus627
- hypoacusis504
- headache499
- diarrhoea462
- blood glucose increased458
- nausea453
- alopecia441
- endocrine ophthalmopathy375
- pain360
- anxiety350
- diplopia329
- weight decreased321
- drug ineffective301
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 475 |
| 2021 | 692 |
| 2022 | 727 |
| 2023 | 732 |
| 2024 | 1,869 |
| 2025 | 702 |
| 2026 | 754 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,208 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endocrine ophthalmopathySignal | 375 | 2690.4 | 2358.0 | 571,088 |
| tinnitusSignal | 627 | 48.9 | 45.4 | 29,032 |
| diplopiaSignal | 329 | 45.3 | 40.8 | 14,052 |
| hypoacusisSignal | 504 | 41.9 | 38.5 | 19,863 |
| muscle spasmsSignal | 1,156 | 22.4 | 21.3 | 23,668 |
| blood glucose increasedSignal | 458 | 8.6 | 7.9 | 3,093 |
| alopeciaSignal | 441 | 8.0 | 7.3 | 2,693 |
| anxietySignal | 350 | 4.4 | 3.9 | 911 |
| weight decreasedSignal | 321 | 4.1 | 3.7 | 749 |
| fatigueSignal | 822 | 3.7 | 3.5 | 1,704 |
| headacheSignal | 499 | 2.8 | 2.6 | 599 |
| diarrhoeaSignal | 462 | 2.5 | 2.3 | 439 |
| painSignal | 360 | 2.1 | 1.9 | 204 |
| nauseaSignal | 453 | 2.0 | 1.9 | 242 |
| drug ineffective | 301 | 0.8 | 0.7 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.